Microfluidics engineered autologous nanovaccine for activating and visualizing antitumor activity
Open Access
- 6 February 2026
- journal article
- research article
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
Abstract
Tumor-derived extracellular vesicles (TEVs) are promising autologous cancer vaccines due to their intrinsic tumor-associated antigens. However, their transKeywords
Funding Information
- Natural Science Foundation of China (82071919)
- Natural Science Foundation of China (82071919)
This publication has 40 references indexed in Scilit:
- A Dendritic Cell‐Nanogel Conjugate for Tumor‐Draining Lymph Node‐Specific PD‐L1 BlockadeAdvanced Materials, 2025
- Effect of Extracellular Vesicles Derived From Tumor Cells on Immune EvasionAdvanced Science, 2025
- The tumor-draining lymph node as a reservoir for systemic immune surveillanceTrends in Cancer, 2023
- Molecular characteristics and clinical behaviour of epithelial ovarian cancersCancer Letters, 2023
- Advances in Extracellular Vesicle Nanotechnology for Precision TheranosticsAdvanced Science, 2022
- Response criteria for immunotherapy and the radiologic patterns of immune-related adverse eventsEuropean Journal of Radiology, 2022
- The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph NodesCancer Cell, 2020
- Emerging Prospects of Exosomes for Cancer Treatment: From Conventional Therapy to ImmunotherapyAdvanced Materials, 2020
- Structures and Mechanisms in the cGAS-STING Innate Immunity PathwayImmunity, 2020
- Simultaneous in vivo tracking of dendritic cells and priming of an antigen-specific immune responseBiomaterials, 2011